Suvretta Capital Management is raising money for a new fund that will launch on April 1.
The fund, called Averill, will be completely separate from Suvretta’s existing funds but will use the firm’s infrastructure, according to a Suvretta investor.
Averill will be a long-short fund specializing in biotech stocks and led by Kishen Mehta, who has extensive experience in the biotech industry.
Mehta
